Literature DB >> 12135571

Bacterial expression and characterization of mature apolipoprotein A-I.

Stacey E Panagotopulos1, Scott R Witting, Erica M Horace, J Nicholas Maiorano, W Sean Davidson.   

Abstract

Plasma levels of apolipoprotein A-I (apoA-I) are correlated with reduced incidence of heart disease due to the critical role of this protein in reverse cholesterol transport. Because of its diversity of function and poorly understood structure, much research has sought to understand how the structure of apoA-I facilitates its function. A popular approach has been the use of site-directed mutagenesis followed by structural and functional studies. There are a wide variety of expression systems available to produce these mutant proteins including eukaryotic cell lines and prokaryotic cells such as Escherichia coli. Expression in a bacterial system is generally favorable because it can produce large amounts of pure protein quickly and economically through the use of affinity tags on the expressed protein. Unfortunately, many of these systems are not ideal for the production of apolipoproteins because, in many cases, the proteolytic digestion required to remove the affinity tag also cleaves the target protein. Here we describe a method that produces large amounts of recombinant protein that is easily purified using a histidine (His) affinity tag that is cleaved with IgA protease from Neisseria gonorrhoeae. This enzyme does not cleave the wild type apoA-I sequence, leaving intact, mature apoA-I (containing a Thr-Pro- on the N-terminus). We show that this recombinant protein is similar to wild type protein in structure and function using circular dichroism analysis, lipid clearance assays, recombinant particle formation and cholesterol efflux assays. This system is particularly useful for the bacterial production of apolipoproteins because of the extreme specificity of IgA protease for its target cleavage site.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12135571     DOI: 10.1016/s1046-5928(02)00020-7

Source DB:  PubMed          Journal:  Protein Expr Purif        ISSN: 1046-5928            Impact factor:   1.650


  7 in total

1.  Purification of recombinant apolipoproteins A-I and A-IV and efficient affinity tag cleavage by tobacco etch virus protease.

Authors:  Matthew R Tubb; Loren E Smith; W Sean Davidson
Journal:  J Lipid Res       Date:  2009-03-24       Impact factor: 5.922

2.  Expression of the C-terminal domain of human apolipoprotein A-I using a chimeric apolipoprotein.

Authors:  Daniel E Sallee; James V C Horn; Lukas A Fuentes; Paul M M Weers
Journal:  Protein Expr Purif       Date:  2017-06-15       Impact factor: 1.650

3.  A facile method for isolation of recombinant human apolipoprotein A-I from E. coli.

Authors:  Nikita Ikon; Jennifer Shearer; Jianfang Liu; Jesse J Tran; ShiBo Feng; Ayako Kamei; Jennifer A Beckstead; Robert S Kiss; Paul M Weers; Gang Ren; Robert O Ryan
Journal:  Protein Expr Purif       Date:  2017-03-20       Impact factor: 1.650

4.  Apolipoprotein A-IV inhibits experimental colitis.

Authors:  Thorsten Vowinkel; Mikiji Mori; Christian F Krieglstein; Janice Russell; Fumito Saijo; Sulaiman Bharwani; Richard H Turnage; W Sean Davidson; Patrick Tso; D Neil Granger; Theodore J Kalogeris
Journal:  J Clin Invest       Date:  2004-07       Impact factor: 14.808

5.  The role of hydrophobic and negatively charged surface patches of lipid-free apolipoprotein A-I in lipid binding and ABCA1-mediated cholesterol efflux.

Authors:  Loren E Smith; W Sean Davidson
Journal:  Biochim Biophys Acta       Date:  2009-09-24

6.  An analysis of the role of a retroendocytosis pathway in ABCA1-mediated cholesterol efflux from macrophages.

Authors:  Loren E Faulkner; Stacey E Panagotopulos; Jacob D Johnson; Laura A Woollett; David Y Hui; Scott R Witting; J Nicholas Maiorano; W Sean Davidson
Journal:  J Lipid Res       Date:  2008-03-22       Impact factor: 5.922

Review 7.  The unsolved mystery of apoA-I recycling in adipocyte.

Authors:  Shuai Wang; Dao-quan Peng; Yuhong Yi
Journal:  Lipids Health Dis       Date:  2016-02-24       Impact factor: 3.876

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.